Product Description
Simcha IL-18 is developing ST-067 as a treatment for relapsed or refractory solid tumors. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04787042)
Mechanisms of Action: IL18 Activator
Novel Mechanism: Yes
Modality: Cytokine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Simcha IL-18
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04787042 |
ST-067-001 | P2 |
Recruiting |
Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Melanoma|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma |
2025-06-30 |
23% |
2024-11-16 |
Primary Endpoints |